{"id":"background-nsaid","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal ulceration or bleeding"},{"rate":"5-15","effect":"Dyspepsia"},{"rate":"3-10","effect":"Nausea"},{"rate":"1-2","effect":"Cardiovascular events (myocardial infarction, stroke)"},{"rate":"1-5","effect":"Renal impairment"},{"rate":"2-5","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL139","moleculeType":"Small molecule","molecularWeight":"296.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NSAIDs block COX-1 and/or COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses, pain signaling, and fever regulation. By reducing prostaglandin levels, NSAIDs provide analgesic, anti-inflammatory, and antipyretic effects. The specific COX selectivity profile (COX-1 vs COX-2 inhibition) varies by individual NSAID and influences both efficacy and gastrointestinal safety.","oneSentence":"NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:27.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory pain and fever (general indication for NSAID class)"}]},"trialDetails":[{"nctId":"NCT01885078","phase":"PHASE3","title":"An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06-27","conditions":"Rheumatoid Arthritis","enrollment":2877},{"nctId":"NCT01455415","phase":"PHASE3","title":"Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-12","conditions":"Painful Diabetic Peripheral Neuropathy","enrollment":306},{"nctId":"NCT01712009","phase":"PHASE2","title":"NOLAN: Naproxen or Loratadine and Neulasta","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-01","conditions":"Bone Pain in Stage I - III Breast Cancer","enrollment":600},{"nctId":"NCT01258738","phase":"PHASE3","title":"Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Spondylitis, Ankylosing","enrollment":225},{"nctId":"NCT00424294","phase":"PHASE2","title":"A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-06","conditions":"Arthritis, Rheumatoid","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3326,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Background NSAID","genericName":"Background NSAID","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Inflammatory pain and fever (general indication for NSAID class).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}